H-2Ld MuLV gp70 Tetramer-SPSYVYHQF-PE

MBL

Catalog No: MBL-TS-M521-1

Anti-mouse CD8 clone choice is critical when mouse MHC I tetramers, as some clones, including 53-6.7, lead to high background staining of all CD8+ T cells, rather than the antigen-specific ones. For best results, clone KT15, available from MBL International in FITC (K0227-4)is recommended. Additional information can be found in the datasheet that accompanies mouse class I tetramers, as well as the following reference containing a protocol for performing a cross titration series for optimization: Current Protocols in Immunology, MHC-Peptide tetramers to Visualize Antigen-Specific T Cells, Section 17.3.23-24, Supplement 178

Citations for H-2Ld MuLV gp70 Tetramer-SPSYVYHQF-PE – 5 Found

Iida, Yuichi; Harashima, Nanae; Motoshima, Takanobu; Komohara, Yoshihiro; Eto, Masatoshi; Harada, Mamoru. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. Cancer Science. 2017;108(10):1974-1984. 

Selby, Mark J; Engelhardt, John J; Johnston, Robert J; Lu, Li-Sheng; Han, Minhua; Thudium, Kent; Yao, Dapeng; Quigley, Michael; Valle, Jose; Wang, Changyu; Chen, Bing; Cardarelli, Pina M; Blanset, Diann; Korman, Alan J. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. Plos One. 11(9):e0161779. 

Sivick, Kelsey E; Desbien, Anthony L; Glickman, Laura Hix; Reiner, Gabrielle L; Corrales, Leticia; Surh, Natalie H; Hudson, Thomas E; Vu, Uyen T; Francica, Brian J; Banda, Tamara; Katibah, George E; Kanne, David B; Leong, Justin J; Metchette, Ken; Bruml, Jacob R; Ndubaku, Chudi O; McKenna, Jeffrey M; Feng, Yan; Zheng, Lianxing; Bender, Steven L; Cho, Charles Y; Leong, Meredith L; van Elsas, Andrea; Dubensky, Thomas W Jr; McWhirter, Sarah M. Magnitude of Therapeutic STING Activation Determines CD8(+) T Cell-Mediated Anti-tumor Immunity. Cell Reports. 2018;25(11):3074-3085.e5. 

Wang, Bei; Zhang, Wen; Jankovic, Vladimir; Golubov, Jacquelynn; Poon, Patrick; Oswald, Erin M; Gurer, Cagan; Wei, Joyce; Ramos, Ilyssa; Wu, Qi; Waite, Janelle; Ni, Min; Adler, Christina; Wei, Yi; Macdonald, Lynn; Rowlands, Tracey; Brydges, Susannah; Siao, Jean; Poueymirou, William; MacDonald, Douglas; Yancopoulos, George D; Sleeman, Matthew A; Murphy, Andrew J; Skokos, Dimitris. Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype. Science Immunology. 2018;3(29) 

Freeman, Zachary T; Nirschl, Thomas R; Hovelson, Daniel H; Johnston, Robert J; Engelhardt, John J; Selby, Mark J; Kochel, Christina M; Lan, Ruth Y; Zhai, Jingyi; Ghasemzadeh, Ali; Gupta, Anuj; Skaist, Alyza M; Wheelan, Sarah J; Jiang, Hui; Pearson, Alexander T; Snyder, Linda A; Korman, Alan J; Tomlins, Scott A; Yegnasubramanian, Srinivasan; Drake, Charles G. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. The Journal Of Clinical Investigation. 2020;130(3):1405-1416.